| Literature DB >> 22848766 |
Leonore Lovis1, Tippi K Mak, Khampheng Phongluxa, Phonepasong Ayé Soukhathammavong, Youthanavanh Vonghachack, Jennifer Keiser, Penelope Vounatsou, Marcel Tanner, Christoph Hatz, Jürg Utzinger, Peter Odermatt, Kongsap Akkhavong.
Abstract
BACKGROUND: Schistosomiasis and opisthorchiasis are of public health importance in Southeast Asia. Praziquantel (PZQ) is the drug of choice for morbidity control but few dose comparisons have been made.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22848766 PMCID: PMC3404075 DOI: 10.1371/journal.pntd.0001726
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Flowchart of subjects with cure and egg reduction rates.
Cure and egg reduction rates are presented for O. viverrini and S. mekongi infections following 40 mg/kg and 75 mg/kg (50 mg/kg+25 mg/kg 4 hours apart) PZQ treatment considering (a) the maximum sampling effort (3×3, 3 stool specimens with triplicate Kato-Katz thick smears per specimen); (b) the minimum sampling effort (1×1, single Kato-Katz thick smear from the first stool specimen).
Baseline prevalence of infection of the main helminth species and infection intensity among egg-positive children.
| Full 3×3 data at baseline ( | Full 3×3 data at baseline and 28–30 days posttreatment follow-up ( | |||||||
| Helminth species | Prevalence (%) | 95% CI | Infection intensity (EPG) | 95% CI | Prevalence (%) | 95% CI | Infection intensity (EPG) | 95% CI |
|
| 87.8 | 79.2–93.7 | 25 | 18–33 | 85.9 | 75.0–93.4 | 28 | 20–40 |
|
| 98.9 | n.d. | 342 | 229–510 | 98.4 | n.d. | 337 | 201–566 |
| Hookworm | 96.7 | n.d. | 321 | 221–464 | 95.3 | n.d. | 252 | 157–403 |
|
| 23.3 | 15.1–33.4 | 13 | 7–24 | 18.8 | 10.1–30.5 | 9 | 4–21 |
|
| 7.8 | 3.2–15.4 | 124 | 9–1,506 | 6.3 | n.d. | 16 | 1–141 |
|
| 7.8 | 3.2–15.4 | 12 | 2–53 | 6.3 | n.d. | 10 | 0–242 |
|
| 6.7 | 2.5–13.9 | 6 | 2–17 | 4.7 | n.d. | 9 | 0–112 |
Study was carried out among 93 children in primary and secondary schools on Don Long Island, Khong district, Champasack province, Lao PDR in February and March 2007. Full 3×3 data refers to children who provided 3 stool specimens over consecutive days, with triplicate Kato-Katz thick smear examinations per stool specimen.
CI, confidence interval; EPG, eggs per gram of stool; n.d., not defined.
S. mekongi infection intensity before (D0) and posttreatment (D28) and egg reduction rate for maximum and minimum diagnostic effort.
| Treatment | Maximum diagnostic effort (3×3 datasets, | Minimum diagnostic effort (1×1 datasets, | |||||||||||
| Infection intensity | n | # cured | % cured | D0 GM (EPG) | D28 GM (EPG) | ERR (%) | n | # cured | % cured | D0 GM (EPG) | D28 GM (EPG) | ERR (%) | |
| 40 mg/kg | All infections | 32 | 24 | 75.0 | 21.0 | 0.75 | 96.4 | 21 | 18 | 85.7 | 47.6 | 1.00 | 97.9 |
| 1–99 EPG | 27 | 20 | 74.1 | 13.1 | 0.81 | 93.8 | 16 | 13 | 81.3 | 22.4 | 1.48 | 93.4 | |
| 100–399 EPG | 3 | 3 | 100 | 157.1 | 0 | 100 | 2 | 2 | 100 | 200.8 | 0 | 100 | |
| ≥400 EPG | 2 | 1 | 50.0 | 451.3 | 1.52 | 99.7 | 3 | 3 | 100 | 923.0 | 0 | 100 | |
| 75 mg/kg | All infections | 26 | 21 | 80.8 | 26.6 | 0.52 | 98.1 | 19 | 18 | 94.7 | 63.5 | 0.23 | 99.6 |
| 1–99 EPG | 22 | 17 | 77.3 | 18.2 | 0.64 | 96.5 | 14 | 13 | 92.9 | 45.1 | 0.32 | 99.3 | |
| 100–399 EPG | 4 | 4 | 100 | 201.7 | 0 | 100 | 5 | 5 | 100 | 163.6 | 0 | 100 | |
| ≥400 EPG | 0 | 0 | na | na | na | na | 0 | 0 | na | na | na | na | |
EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; na, not applicable.
O. viverrini infection intensity before (D0) and posttreatment (D28) and egg reduction rate for maximum and minimum diagnostic effort.
| Treatment | Maximum diagnostic effort (3×3 datasets, | Minimum diagnostic effort (1×1 datasets, | |||||||||||
| Infection intensity | n | # cured | % cured | D0 GM (EPG) | D28 GM (EPG) | ERR (%) | n | # cured | % cured | D0 GM (EPG) | D28 GM (EPG) | ERR (%) | |
| 40 mg/kg | All infections | 35 | 25 | 71.4 | 307.4 | 0.99 | 99.7 | 35 | 33 | 94.3 | 411.8 | 0.26 | 99.94 |
| 1–999 EPG | 24 | 18 | 75.0 | 96.4 | 0.48 | 99.5 | 24 | 24 | 100 | 142.3 | 0 | 100 | |
| 1,000–9,999 EPG | 9 | 6 | 66.7 | 2,460 | 2.1 | 99.92 | 9 | 7 | 77.8 | 2,817 | 1.4 | 99.95 | |
| ≥10,000 EPG | 2 | 1 | 50.0 | 27,344 | 9.0 | 99.97 | 2 | 2 | 100 | 23,778 | 0 | 100 | |
| 75 mg/kg | All infections | 29 | 28 | 96.6 | 308.1 | 0.05 | 99.98 | 35 | 35 | 100 | 383.7 | 0 | 100 |
| 1–999 EPG | 20 | 20 | 100 | 103.7 | 0.00 | 100 | 24 | 24 | 100 | 181.1 | 0 | 100 | |
| 1,000–9,999 EPG | 9 | 8 | 88.9 | 3,424.2 | 0.16 | 100 | 10 | 10 | 100 | 1,568 | 0 | 100 | |
| ≥10,000 EPG | 0 | 0 | na | na | na | na | 1 | 1 | 100 | 18,816 | 0 | 100 | |
EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; na, not applicable.
Solicited adverse events reported 24 hours following PZQ administration (n = 93).
| Total no. of reports | Reports graded as severe | ||||||
| Organ class | Symptoms | 40 mg/kg | 75 mg/kg |
| 40 mg/kg | 75 mg/kg |
|
| ( | (n = 39) | ( | ( | ||||
| Systemic | Allergic reaction | 1 | 0 | 0.32 | 0 | 0 | |
| Fever | 0 | 2 | 0.15 | 0 | 0 | ||
| Headache | 27 | 31 | 0.23 | 0 | 0 | ||
| Anxiety | 1 | 2 | 0.54 | 0 | 0 | ||
| Fatigue | 24 | 28 | 0.27 | 0 | 0 | ||
| Vertigo/dizziness | 20 | 23 | 0.42 | 0 | 1 | 0.31 | |
| Gastro-intestinal | Nausea | 9 | 12 | 0.41 | 0 | 0 | |
| Vomiting | 5 | 11 | 0.08 | 0 | 2 | 0.15 | |
| Diarrhea | 7 | 5 | 0.56 | 0 | 0 | ||
| Constipation | 2 | 0 | 0.16 | 0 | 0 | ||
| Abdominal pain | 23 | 27 | 0.28 | 0 | 0 | ||
| Cardiovascular | Palpitations | 4 | 6 | 0.47 | 0 | 0 | |
| Hypotension | 1 | 7 | 0.02 | 0 | 0 | ||
| Respiratory | Cough | 1 | 1 | 0.99 | 0 | 0 | |
| Bronchospasm | 1 | 1 | 0.99 | 0 | 0 | ||
| Dyspnea | 1 | 1 | 0.99 | 0 | 0 | ||
*: according to exact χ2 test.
The two study groups were 40 mg/kg vs. 75 mg/kg divided into 2 doses of 50 mg/kg+25 mg/kg, 4 hours apart.
Figure 2Cumulative prevalence according to the sampling effort.
Cumulative infection prevalences for (a) S. mekongi and (b) O. viverrini by the number over consecutive days of stool specimen collection (x-axis). Each point on a curve represents a cumulative prevalence value for each sampling effort (number of Kato-Katz thick smears per stool specimen). At baseline (day 0), n = 90; after treatment (days 28–30), n = 66.
Sensitivity of different sampling efforts to detect S. mekongi and O. viverrini infections.
| Sensitivity of different Kato-Katz thick smear sampling efforts | ||||||||
| Helminth species | Baseline survey ( | Days 28–30 posttreatment follow-up ( | ||||||
| 1 stool1 smear | 1 stool3 smears | 3 stools1 smear | 3 stools3 smears | 1 stool1 smear | 1 stool3 smears | 3 stools1 smear | 3 stools3 smears | |
| n (%) | n (%) | n (%) | n (‘gold’ standard) | n (%) | n (%) | n (%) | n (‘gold’ standard) | |
|
| 36 (45.6) | 54 (68.4) | 65 (82.3) | 79 (100) | 2 (14.3) | 3 (21.4) | 8 (57.1) | 14 (100) |
|
| 74 (83.1) | 84 (94.4) | 84 (94.4) | 89 (100) | 2 (18.2) | 4 (36.4) | 5 (45.4) | 11 (100) |
Study was carried out among 93 children in primary and secondary schools on Don Long Island, Khong district, Champasack province, Lao PDR in February and March 2007. Sensitivity is compared before (n = 90) and after PZQ administration (n = 66), using the maximum sampling effort as the diagnostic ‘gold’ standard for the following sampling efforts: 1×1 sampling effort examines the first Kato-Katz thick smear only; 1×3 examines the first stool specimen by triplicate Kato-Katz thick smears; 3×1 examines 3 stool specimens by a single Kato-Katz thick smear for each specimen.
Figure 3Geometric mean fecal egg counts according to the sampling effort.
Geometric mean fecal egg counts before and after PZQ treatment, by the number of days of stool specimen collection (x-axis), based on children diagnosed “infected” following maximum Kato-Katz thick smear sampling effort. (a) S. mekongi infected at baseline (day 0), n = 79; days 28–30 after treatment, n = 14; and (b) O. viverrini infected at baseline (day 0), n = 89; days 28–30 after treatment, n = 11. Each point on a curve represents the geometric mean fecal egg count for each sampling effort (number of Kato-Katz thick smears examined per stool specimen).